shutterstock_1174421515_eyesonmilan

eyesonmilan / Shutterstock.com

1 April 2021AmericasMuireann Bolger

US govt doesn’t have remdesivir patent rights, says GAO

The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office (GAO).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Russian drugmakers bypass Gilead to unveil COVID-19 generic

4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

More on this story

Russian drugmakers bypass Gilead to unveil COVID-19 generic

4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

More on this story

Russian drugmakers bypass Gilead to unveil COVID-19 generic

4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

Gilead told to waive remdesivir patent rights

2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages